The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
In Phase 2b/3 clinical trials, Dapagliflozin has been shown to raise HDL cholesterol levels
by about 4 mg/dl (1 mmol/l), which is generally considered a clinically-meaningful change. As
this HDL cholesterol increase is carried out with concomitant improvement in glucotoxicity
and body weight reduction, it is possible that treatment with Dapagliflozin also improves HDL
function. This is important because clinical, epidemiological and experimental studies
indicate that HDL function may be more important than HDL cholesterol levels in determining
the protective cardiovascular effects of HDL particles. In addition, knowing the effects of
Dapagliflozin on HDL function can help interpreting the increase in HDL cholesterol levels
observed in Dapagliflozin-treated patients. Finally, discovery of extra-glycemic effects of
Dapagliflozin will shed new light on the potential benefits of therapy with Dapagliflozin and
SGLT2i in general. So far, no study evaluated the effects of Dapagliflozin (or other SGLT2i)
on HDL function.
The investigators hypothesize that Dapagliflozin, in addition to raising HDL cholesterol
levels, also increases HDL functionality, measured as reverse cholesterol transport and
anti-oxidant capacity, in patients with T2DM